Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shasun Pharmaceuticals and Debiopharm have entered into a licensing agreement to manufacture and commercialize Huperzine-A, which is a potent and reversible acetylcholinesterase inhibitor.
Subscribe to our email newsletter
As per the agreement, Shasun Pharmaceuticals will use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical markets.
Debiopharm president and founder Dr. Mauvernay said, "Clinical studies have demonstrated the drug to enable significant improvement in both memory deficit and cognitive performance and we are excited to have the opportunity to add value to this technology while contributing to improve people’s quality of life."
Shasun Pharmaceuticals president Dr. Michel Spagnol said that the agreement highlights the company’s commitment to delivering cutting-edge science in all the processes through the global research and development network.
Huperzine-A is commercially available through Shasun Pharmaceuticals.